FATE NK100

Drug Profile

FATE NK100

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fate Therapeutics
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 08 Aug 2017 US FDA approves an IND application for FATE NK100 in Ovarian cancer (Second-line therapy or greater)
  • 13 Jul 2017 Masonic Cancer Center plans a phase I trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Second-line therapy or greater) in USA in October 2017 (NCT03213964)
  • 31 May 2017 US FDA approves an IND application for FATE NK100 in Solid tumours (Combination therapy, Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top